AIM ImmunoTech Ampligen shows encouraging prophylactic effect v. Covid

Results from a 3D-mucociliary tissue culture showed AIM ImmunoTech’s (AIM +12.3%) Ampligen, a dsRNA TLR3 agonist, decreased SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels.

“We are pleased with these results, as they establish Ampligen’s bio-activity against SARS-CoV-2 as well as support our decision to test Ampligen in humans as an intranasal prophylaxis and early-onset therapy against COVID-19,” said its CEO Thomas Equels

https://seekingalpha.com/news/3609417-aim-immunotechs-ampligens-shows-encouraging-prophylactic-effect-against-covidminus-19